Cambridge Cognition and Altreos Research Partners, Inc. join forces as FDA guidelines drive demand for Human Abuse Liability studies

Cambridge, UK, August 30, 2014: The release of two key draft FDA Guidances on abuse liability assessments on drugs\* and abuse-deterrent products has resulted in increased demand for human abuse liability studies. In response, Cambridge Cognition, the global leader in touchscreen cognitive assessments for clinical trials, has formed a scientific partnership with Altreos Research Partners, Inc., a leading provider of scientific, regulatory and operational input on abuse liability assessments.

According to Scott Goss, Chief Commercial Officer at Cambridge Cognition, “This is an exciting development in a relationship that has grown significantly in the last year. The aim of the scientific partnership is to maximize the combined benefits of Altreos' extensive knowledge and experience with Cambridge Cognition's industry leading solutions for delivering computerized abuse liability tests to pharmaceutical companies assessing the abuse potential of their product.”

Goss added that the Altreos team has already contributed their knowledge and expertise to the development of Cambridge Cognition’s newly launched cloud-based abuse liability product, CTIS-AL. As part of the partnership, Altreos will continue to support Cambridge Cognition in ensuring that CTIS-AL remains the market leading solution for performing computerized abuse liability studies globally. This will involve intensified joint activities such as webinars starting in autumn 2014. In addition, Cambridge Cognition clients will now have early access to Altreos’ broad range of consulting services to support them in the planning of their abuse liability studies.

Dr. Megan Shram of Altreos Research Partners, added: “We are pleased to be working with Cambridge Cognition to support sponsors developing CNS products and abuse-deterrent formulations. Given the importance of the human abuse liability study in the interpretation of overall abuse potential (or deterrence), we need to be confident that study results are reliable and accurate. With an appropriately designed study and a platform such as CTIS-AL, we can be increasingly assured that the data are of high quality and can be meaningfully interpreted.”

\* *Drugs with abuse potential include compounds that either affect the Central Nervous System (CNS), are chemically or pharmacologically similar to other drugs with known abuse potential or exhibit psychoactive effects such as sedation, euphoria or mood change.*

Notes to editors:

Cambridge Cognition  
Cambridge Cognition is a world leading provider of computerized cognitive assessment products. The company’s range of touchscreen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used extensively by scientists in academic research, and in the pharmaceutical industry, to accelerate the development of drugs that are safe and effective for mental health.

The Company has quickly established a leading position in computerized assessment of Human Abuse Liability, now leveraging a new product on the recently launched cloud-computing platform, *Cantab Connect*, for pharmaceutical companies to conduct enhanced Abuse Liability studies on an iPad. See [www.cantab.com/HAL](http://www.cantab.com/HAL) for details.

[www.cambridgecognition.com](http://www.cambridgecognition.com)

[press@camcog.com](mailto:press@camcog.com)

Altreos Research Partners  
Altreos Research Partners offer a breadth of expertise and research experience, and have been involved in the design and evaluation of over one hundred Phase 1 studies, including more than 50 abuse liability studies. Their expertise in abuse liability has led to invitations to present at meetings with FDA involvement, which have helped shape the regulatory landscape in this evolving area of research.

[www.altreos.com](http://www.altreos.com)

[contact@altreos.com](mailto:contact@altreos.com)